Fundraising FoxNew York · Growth–Late Stage · 7 people tracked
Also known as ALLY BRIDGE GROUP (NY) LLC · ALLY BRIDGE GROUP (PE) LLC
Find your way into Ally Bridge Group
3,179 people in our graph can introduce you to the Ally Bridge Group team.
Sign up to see every warm intro you have to Ally Bridge Group
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ally Bridge Group team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Ally Bridge Group is a global healthcare investment manager targeting high-impact life sciences innovation in both private and public markets. Combining scientific and clinical research with M&A and capital markets expertise, the firm seeks investment opportunities across the capital structure that address unmet medical needs. It operates a public equity strategy alongside private investments, backing biotech and life sciences companies developing next-generation therapies.
Source: firm website, verified Sep 29, 2026.
Team · 7 people
from the firm's website & curated
Founder mafia
2 people who came through Ally Bridge Group went on to found or lead other companies.
What they invest in
from 52 of 54 portfolio companiesHealthtech ×32Biotech ×28Medical Devices ×22AI & Machine Learning ×12Digital Health ×8Deep Tech ×6SaaS ×5Robotics ×3
HQs:United States×41Canada×1France×1
Investments · 54 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 92024 · 32023 · 12021 · 102020 · 12019 · 12018 · 32017 · 12015 · 12014 · 12011 · 136 dated
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investors3B Future Health FundDecheng CapitalVivo CapitalOrbiMed
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+3 more
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Co-investorsBand of AngelsHealthCapKaiser Permanente VenturesKleiner PerkinsLatterell Venture PartnersMontreux Equity Partners
Rapid Micro Biosystems manufactures automated laboratory testing systems and consumables for pharmaceutical and cell therapy manufacturers to conduct microbiological quality control testing, replacing manual methods with platform-based analysis.
HealthtechLowell, US
Robert Spignesi(Executive Officer, Director)inStephen H. Delity(Executive Officer, Director)Michael J. Mullen(Executive Officer)
BoardDavid Hirsch(Director)Richard S. Kollender(Director)Fred Cohen(Director)
Co-investorsEndeavour VisionKleiner PerkinsLongitude CapitalXeraya Capital
LightForce develops generative braces using artificial intelligence and 3D printing technology to create individualized orthodontic appliances tailored to each patient.
Advanced ManufacturingAI & Machine LearningHardwareHealthtechMedical DevicesBoston, US
Alfred Griffin, DMD, PhD(Chief Product Officer / Founder)Dr. Lou Shuman, DMD, CAGS(Co-founder)Erica Rogers(Chief Executive Officer)inAlfred Griffin(Founder)Lou Shuman(Founder)
Co-investorsKleiner PerkinsAM VenturesDIAMatrixMatter Venture PartnersOmega Venture Partners+3 more
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)inKevin Tracey(Founder)
Co-investorsNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersAsahi Kasei Corporate Venture CapitalCatalio Capital Management, LPCitta Capital+8 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSanofi VenturesSV Health InvestorsTenmile+2 more
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)inDerrick Sung(Executive Officer)inMatthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)inAndre Cheng(Executive Officer)inFred Dinger(Executive Officer, Director)in
Co-investorsLaunchCapitalOrbiMedQuesta CapitalTargeted Technology FundsHorizon
BiotechCincinnati, US
Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)
Co-investorsCincyTechSofinnova VenturesOrbiMed
BiotechSan Diego, US
Francois Ferre(Director)Magda Marquet(Director)Jorge Garces(Executive Officer)inGreg Hamilton(Executive Officer, Director)Carin Sandvik(Executive Officer)Jeffrey G. Black(Executive Officer)
Co-investorsBioBritTelegraph Hill PartnersVivo CapitalWuXi Healthcare Ventures
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverJanus Henderson InvestorsRevelation Partners+4 more
Biobeat develops a cuff-less, ambulatory blood pressure monitoring system built around a proprietary PPG sensor and a platform for tracking vital signs, aimed at helping physicians diagnose and manage hypertension.
Digital HealthHealthtechMedical Devices
Arik B.(Founder)inArik Ben Ishay(Founder & CEO)Johanan May(Founder, SVP & CTO)inIsrael Sarussi(Founder, SVP R&D)inMichael Gioffredi(CCO)in
BoardRaymond W. Cohen(Chairman of the Board)
Co-investorsOrbiMedRaptor Group
Calyxo develops medical devices for kidney stone removal, specifically a minimally invasive CVAC (Cavitation-Enabled Ablation and Clearance) system that has been FDA-cleared.
HealthtechMedical DevicesPleasanton, US
Chris Buchko(Executive Officer)inDouglas Hughes(Executive Officer, Director)Jee Shin(Executive Officer, Director)inMark Kidd(Executive Officer)Joe Catanese(Executive Officer, Director)
BoardRyan Drant(Director)in
Co-investorsQuesta CapitalJanus Henderson Investors
Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.
BiotechHealthtechMedical DevicesKirkland, US
Frederick A. Stewart(Executive Officer, Director)Rick Wypych(Executive Officer)in
BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)Gerry Brunk(Director)in
Co-investorsAPERTURE Venture PartnersLumira VenturesRedbus VenturesClaret Capital PartnersJefferiesM.H. Carnegie & Co.
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalWellington ManagementJanus Henderson InvestorsPerceptive Xontogeny Venture+1 more
Climb is a French wealth management service that combines advisors with technology to grow clients' assets through an open-architecture selection of investment products (life insurance, retirement PER, real estate, private equity, tax-reduction schemes, crypto).
FintechSaaS
Aldric Emié(CEO)in
Co-investorsKima VenturesRA CapitalREDMILE
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeDe Novo VenturesJanus Henderson Investors+3 more
Elevage Medical appears to be a medical or healthcare company with a team including physicians, board members, and operational staff, though the specific business activities are not detailed on this team page.
Digital HealthHealthtechMedical Devices
Evan Melrose(Chief Executive Officer & Partner)inMichael Wasserman(Chief Operating Officer & Partner)in
Co-investorsPatient Square Capital
Healthcare-enabling research organization that embeds clinical trials into everyday care using electronic health record data.
HealthtechAustin, US
Chad Moore(Founder)inJohn Potthoff(Founder)inJacylyn Bodmer(Chief Information Officer)Karen Flaherty(Vice President, Finance)inAmy Staedtler(Chief Legal Officer)inScott Treiber(Chief Operating Officer)in
Co-investorsExcelerate Health VenturesHatteras Venture PartnersNoro-Moseley PartnersNorwest Venture PartnersShumway Capital
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Co-investorsabrdn plcAngelini VenturesFidelity InvestmentsJanus Henderson InvestorsSanofi Ventures
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalCatalyst InvestorsFidelity Investments+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeGalvanize Climate SolutionsFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+4 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Co-investorsNorwest Venture PartnersATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson InvestorsPerceptive Xontogeny Venture+2 more
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Li Chen(Founder)
Co-investorsARCH Venture PartnersF-Prime CapitalVenrock6 Dimensions CapitalBlue Pool CapitalEight Roads Ventures+2 more
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Altium CapitalAmgen VenturesDroia VenturesFrazier Healthcare PartnersNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+6 more
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsEmpire AngelsVoyager CapitalAmed VenturesAscension VenturesBain Capital Life SciencesCatalio Capital Management+4 more
Insightec develops Exablate Neuro, an MRI-guided focused ultrasound platform that treats Essential Tremor and tremor-dominant Parkinson's Disease through an incision-free outpatient procedure.
HealthtechMedical DevicesTirat Carmel
Roni Karie(Vice President - Finance)Shirel Aroshase(Vice President - Human Resources)inEyal Zadicario(General Manager)inMenashe Frank(Vice President - Legal)inJun (Jim) Tao(Chief Operating Officer)inMaurice R. Ferre(Chairman and Chief Executive Officer)in
Co-investorsCatalio Capital Management, LPExigent CapitalGEOCJazzya InvestmentsKoch Disruptive TechnologiesKrillion Ventures+6 more
IsoPlexis (now part of Bruker Cellular Analysis) provides single-cell functional profiling technology used to discover therapeutic antibodies, interrogate T cells for novel cell therapies, and accelerate cell line development.
BiotechDeep TechMedical DevicesNew Haven, US
Rong Fan(Director)Sean McKay(Executive Officer, Director)Sean Mackay(Executive Officer, Director)
BoardDaniel Wagner(Director)John Conley(Director)inGregory Ho(Director)
Co-investorsConnecticut InnovationsIronwood CapitalNorthpond VenturesSpring Mountain Capital
Mainstay provides an AI-powered platform that enables higher education institutions to engage students through proactive, personalized coaching and messaging.
AI & Machine LearningEdTechHR TechSaaSArlington, US
Andrew Magliozzi(Founder)inKirk Daulerio(Co-Founder, Vice President, Community)in
BoardKEVIN TALBOT(Director)
Co-investorsAlumni VenturesBisk VenturesEastward Capital PartnersFundersClubK Street CapitalMichelson 20MM Foundation+12 more
Irish company developing an advanced neurostimulation device.
HealthtechPlymouth, US
Dan Sachs(Director)Peter Crosby(Executive Officer, Director)inJason Hannonin
BoardManus Rogan(Director)inAntoine Papiernik(Director)in
Co-investorsFountain Healthcare PartnersIreland Strategic Investment FundSeventure PartnersSofinnova PartnersViking GlobalGilde Healthcare+1 more
Neurolutions makes IpsiHand, an FDA-cleared brain-computer interface system for at-home motor rehabilitation of chronic stroke survivors with arm and hand weakness.
BiotechDigital HealthHealthtechMedical DevicesVan Nuys, US
Eric Leuthardt(Director)inLeo Petrossian(Executive Officer, Director)in
BoardYuanwei Tai(Director)Kevin Reilly(Director)inFred Khosravi(Director)inStavros Vizirgianakis(Director)
Co-investorsExcelestar VenturesAmed Ventures
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's.
BiotechDeep TechHealthtechToronto, CA
Neil Cashman, M.D.(Chief Scientific Officer and Co-founder)EUGENE WILLIAMS(Chairman and Co-Founder)inROBERT GUNDEL(Executive Officer, Director)JANET CLENNETT(Executive Officer)inNeil K. Warma(President and Chief Executive Officer)inELLIOT GOLDSTEIN(Executive Officer, Director)
Co-investorsWellington Management
Quantum Surgical develops Epione, a robotic-assisted percutaneous ablation platform that helps interventional radiologists treat inoperable or difficult early-stage tumors without surgery by guiding needle placement for tumor destruction.
AI & Machine LearningMedical DevicesRoboticsMiami, US
Bertin Nahum(Co-founder & CEO)inChristophe Sibillin(Executive Officer)in
BoardKevin Reilly(Director)inChris Geyen(Director)Frank Yu(Director)inJoseph DeVivo(Director)
Co-investorsBpifrance
SeaGen develops automated robots that monitor aquatic ecosystems and remove pollutants while supporting the growth of beneficial species like seaweed to improve food and water security and reduce atmospheric carbon.
CleantechClimate TechRobotics
Co-investorsAera VCRidgeback CapitalRA CapitalT. Rowe Price
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more
Strateos develops remote access laboratory software and automation platforms that enable scientists to design, execute, and analyze experiments through cloud-based robotics and control systems.
AI & Machine LearningBiotechDeep TechRoboticsSaaSMenlo Park, US
Chris Krueger(Executive Officer)inMark Fischer-Colbrie(Executive Officer, Director)inDavid Lynch, PhD(Chief Executive Officer)Marc Siladi(Chief Operating Officer)in
BoardJoshua Wolfe(Director)Armen Vidian(Director)in
Co-investorsDCVC (Data Collective)Lux CapitalBlueStone Venture PartnersThird Rock VenturesAlumni VenturesDolby Family Ventures+6 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaBain CapitalBain Capital Life Sciences+11 more
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Co-investorsEcoR1 CapitalVida VenturesClarus VenturesPolaris PartnersSoleus Capital
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions into a single member experience, helping people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtechDenver, US
Glen Tullman(Founder)in
Co-investors7wire VenturesAlta PartnersCorewell Health VenturesGeneral CatalystGeodesic CapitalGreatPoint Ventures+9 more
.png)
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Co-investorsARCH Venture PartnersNorthpond Ventures6 Dimensions CapitalApplied VenturesKilonova CapitalPura Vida Investments+3 more
HealthtechSan Jose, US
Greg Vislocky(Director)Charles Chon(Director)Jason Turner(Executive Officer)inPeter Osborne(Executive Officer, Director)Jerry Gibson(Executive Officer, Director)
Co-investorsSCP Ventures, LLC
Vida Health delivers personalized, human-centered digital health care addressing both physical and mental health.
Digital HealthHealthtechSaaSSan Francisco, US
Joe Murad(CEO)Mike Rollain
BoardRichard Frank
Co-investorsAspect VenturesCanvas VenturesGeneral AtlanticHLM Investment PartnersNGP CapitalOwl Capital+7 more
HealthtechCampbell, US
Nersi Nazari(Executive Officer, Director)inSteve Zadig(Executive Officer, Director)in
BoardRichard Feachem(Director)Tom Saunders(Director)
Co-investorsAsahi Kasei Corporate Venture CapitalEssex Woodlands Healthcare PartnersRevelation PartnersMVM Life Science PartnersTrinity Capital
VitalConnect develops wearable biosensor technology for remote and in-hospital patient monitoring, streaming up to 11 vital signs including live ECG to enable physicians to monitor patients recovering at home or in the hospital.
Digital HealthHealthtechMedical Devices
Co-investorsAsahi Kasei Corporate Venture CapitalRevelation PartnersTrinity Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cold GenesysConventus OrthopaedicsShoreline BiosciencesSorrento TherapeuticsSymic BiomedicalTruvic MedicalVevent
Exits · 9
7 IPOs · 2 acquisitions · showing 5Aadi BioscienceNASDAQ: WHWKCG OncologyNASDAQ: CGONGrailNASDAQ: GRALPulmonx Corp.NASDAQ: LUNGRapid Micro BiosystemsNASDAQ: RPID
Portfolio news
latest coverage across their companies
ProMIS Neurosciences · stocktitan.net · Sep 1, 2026
Epicrispr Biotechnologies · finsmes.com · Aug 11, 2026
AdvanCell Isotopes · intelligence360.news · Aug 4, 2026
Pulmonx Corp. · trysignalbase.com · May 12, 2026
Calyxo · calyxoinc.com · May 8, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Pulmonx Corp. | 6.5% | $19.00 | Oct 2020 | $37.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Ally Bridge Group made?
- Ally Bridge Group has 54 tracked investments, 9 of which have exited, including 13 dated in the last 24 months.
- What stage does Ally Bridge Group invest at?
- Ally Bridge Group invests at the Growth, Late Stage stages.
- What sectors does Ally Bridge Group focus on?
- Ally Bridge Group focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Ally Bridge Group located?
- Ally Bridge Group is headquartered in New York, US.
- Does Ally Bridge Group lead rounds?
- Yes, Ally Bridge Group leads investment rounds.
- Who does Ally Bridge Group co-invest with?
- Ally Bridge Group most often shares deals with Aspect Ventures, New Enterprise Associates (NEA), NGP Capital, among 25 tracked co-investors.
Media · Podcasts & interviews
featuring the teamKevin Reilly, Ally Bridge Group | theCUBE + NYSE Wired MedTech Unplugged Series
SiliconANGLE theCUBE · Kevin Reilly
Frank Yu | Ally Bridge Group @ The Hellenic Museum, Melbourne
River X · Frank Yu
Talking Money To Us | Frank Yu - Ally Bridge Group & Julius Garofali - Shaw and Partners - Talk Money To Me | Acast
Frank Yu · shows.acast.com
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
Longitude Capital is a venture growth investor in biotechnology, medical technology, and health solutions companies, investing across both private and public companies to improve clinical outcomes and reduce the cost of care.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.